ATE365742T1 - 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren - Google Patents

4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren

Info

Publication number: ATE365742T1
Authority: AT; Austria
Prior art keywords: aminothieno; pyrimidine; pde7 inhibitors; carbonitrile derivative; pde7
Prior art date: 2003-01-23

Application number

AT04704579T

Other languages

English (en)

Inventor

Belart Emma Terricabras

Matamoros Victor Segarra

Gomez Julio Alvarez-Builla

Lopez Juan Vaquero

Ortega Jose Minguez

Original Assignee

Almirall Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-23

Filing date

2004-01-23

Publication date

2007-07-15

2004-01-23 Application filed by Almirall Lab filed Critical Almirall Lab

2007-07-15 Application granted granted Critical

2007-07-15 Publication of ATE365742T1 publication Critical patent/ATE365742T1/de

Links

MLXWQNSUOXNSER-UHFFFAOYSA-N 4-aminothieno[2,3-d]pyrimidine-6-carbonitrile Chemical class NC1=NC=NC2=C1C=C(C#N)S2 MLXWQNSUOXNSER-UHFFFAOYSA-N 0.000 title abstract 2
229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 title 1
239000002606 phosphodiesterase VII inhibitor Substances 0.000 title 1
101100407335 Dictyostelium discoideum pde7 gene Proteins 0.000 abstract 1
208000037765 diseases and disorders Diseases 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000001575 pathological effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
230000001629 suppression Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Hematology (AREA)
Oncology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Transplantation (AREA)
Endocrinology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT04704579T 2003-01-23 2004-01-23 4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren ATE365742T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ES200300172A ES2217956B1 (es)	2003-01-23	2003-01-23	Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.

Publications (1)

Publication Number	Publication Date
ATE365742T1 true ATE365742T1 (de)	2007-07-15

Family

ID=32749101

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04704579T ATE365742T1 (de)	2003-01-23	2004-01-23	4-aminothieno(2,3-d) pyrimidin -6-carbonitril- derivative zur verwendung als pde7 inhibitoren

Country Status (8)

Country	Link
US (1)	US7662814B2 (de)
EP (1)	EP1590352B1 (de)
JP (1)	JP2006515604A (de)
CN (1)	CN100582112C (de)
AT (1)	ATE365742T1 (de)
DE (1)	DE602004007239T2 (de)
ES (2)	ES2217956B1 (de)
WO (1)	WO2004065391A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004092196A2 (en) *	2003-04-09	2004-10-28	Exelixis, Inc.	Tie-2 modulators and methods of use
US20060014165A1 (en) *	2003-07-14	2006-01-19	Decode Genetics Ehf.	Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
CA2583259C (en) *	2004-10-08	2011-08-02	Astellas Pharma Inc.	Aromatic ring fused pyrimidine derivative
TW200621257A (en)	2004-10-20	2006-07-01	Astellas Pharma Inc	Pyrimidine derivative fused with nonaromatic ring
GB0423653D0 (en)	2004-10-25	2004-11-24	Piramed Ltd	Pharmaceutical compounds
US20090247554A1 (en) *	2006-03-30	2009-10-01	Takeda San Diego, Inc.	Kinase inhibitors
JP5291616B2 (ja) *	2006-04-26	2013-09-18	ジェネンテック，インコーポレイテッド	ホスホイノシチド３−キナーゼ抑制剤化合物およびその使用方法
RU2439074C2 (ru)	2006-04-26	2012-01-10	Ф. Хоффманн-Ля Рош Аг	ПРОИЗВОДНОЕ ТИЕНО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (РI3К)
CN101479274B (zh)	2006-04-26	2013-06-12	霍夫曼-拉罗奇有限公司	药用化合物
GB0608820D0 (en) *	2006-05-04	2006-06-14	Piramed Ltd	Pharmaceutical compounds
KR20090021218A (ko)	2006-06-12	2009-02-27	버텍스 파마슈티칼스 인코포레이티드	이온 채널의 조절제로서 유용한 티에노피리미딘
JP5500990B2 (ja) *	2006-12-07	2014-05-21	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	ホスホイノシチド３−キナーゼ阻害剤化合物及び使用方法
WO2008070740A1 (en) *	2006-12-07	2008-06-12	F.Hoffmann-La Roche Ag	Phosphoinositide 3-kinase inhibitor compounds and methods of use
US8637528B2 (en)	2007-03-27	2014-01-28	Omeros Corporation	Use of PDE7 inhibitors for the treatment of movement disorders
WO2008119057A2 (en) *	2007-03-27	2008-10-02	Omeros Corporation	The use of pde7 inhibitors for the treatment of movement disorders
AU2008298948B2 (en) *	2007-09-12	2014-09-04	F. Hoffmann-La Roche Ag	Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
ES2399774T3 (es) *	2007-09-24	2013-04-03	Genentech, Inc.	Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso
EP2214675B1 (de)	2007-10-25	2013-11-20	Genentech, Inc.	Verfahren zur herstellung von thienopyrimidin-verbindungen
GB0721095D0 (en)	2007-10-26	2007-12-05	Piramed Ltd	Pharmaceutical compounds
US20100093714A1 (en) *	2008-10-13	2010-04-15	Devraj Chakravarty	AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093702A1 (en) *	2008-10-13	2010-04-15	Barbay J Kent	METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
ES2665277T3 (es) *	2009-03-13	2018-04-25	Katholieke Universiteit Leuven K.U. Leuven R&D	Análogos de purina y su uso como agentes inmunosupresores
EP2451811A1 (de) *	2009-05-27	2012-05-16	F. Hoffmann-La Roche AG	Für p110 delta selektive bicyclische indol-pyrimidin-pi3k-hemmerverbindungen und anwendungsverfahren
SG175708A1 (en) *	2009-05-27	2011-12-29	Genentech Inc	Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
EP2595993B1 (de)	2010-07-23	2018-04-18	President and Fellows of Harvard College	Trizyklische proteasomaktivitätsverstärkende verbindungen
US9220715B2 (en)	2010-11-08	2015-12-29	Omeros Corporation	Treatment of addiction and impulse-control disorders using PDE7 inhibitors
KR20130124333A (ko)	2010-11-08	2013-11-13	오메로스 코포레이션	Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
AR090037A1 (es)	2011-11-15	2014-10-15	Xention Ltd	Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
CA2855446C (en)	2011-11-23	2021-04-20	Cancer Research Technology Limited	Thienopyrimidine inhibitors of atypical protein kinase c
WO2013112699A2 (en) *	2012-01-25	2013-08-01	Proteostasis Therapeutics, Inc.	Proteasome activity enhancing compounds
WO2013112706A1 (en) *	2012-01-25	2013-08-01	Proteostasis Therapeutics, Inc.	Proteasome activity modulating compounds
PT3415517T (pt)	2012-09-28	2022-05-13	Takeda Pharmaceuticals Co	Forma cristalina de 1-(4-1-(2,6-difluorobenzil)-5- dimetilaminometil-3-(6-metoxipiridazin-3-il)-2,4-dioxo- 1,2,3,4-tetrahidrotieno(2,3-d)-pirimidin-6-il)fenil)-3- metoxiureia
FR3037957B1 (fr) *	2015-06-23	2019-01-25	Les Laboratoires Servier	Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN108135906A (zh) *	2015-07-24	2018-06-08	路易斯维尔大学研究基金会有限公司	治病化合物、组合物、方法、及化合物制备方法
CN115279769A (zh)	2019-10-10	2022-11-01	梦欧文科学有限责任公司	N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式
CN115232146A (zh) *	2022-08-04	2022-10-25	山东大学	一种2-氨基噻吩并[2,3-d]嘧啶类化合物及其制备方法和应用
AU2023326563A1 (en)	2022-08-18	2025-02-27	Mitodicure Gmbh	Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4008726A1 (de) *	1990-03-19	1991-09-26	Basf Ag	Thieno(2,3-d)pyrimidinderivate
US5869486A (en) *	1995-02-24	1999-02-09	Ono Pharmaceutical Co., Ltd.	Fused pyrimidines and pyriazines as pharmaceutical compounds
JPH1087492A (ja) *	1996-06-25	1998-04-07	Ono Pharmaceut Co Ltd	一酸化窒素産生阻害剤
DE19644228A1 (de)	1996-10-24	1998-04-30	Merck Patent Gmbh	Thienopyrimidine
US6133271A (en) *	1998-11-19	2000-10-17	Cell Pathways, Inc.	Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
DE19953024A1 (de)	1999-11-04	2001-05-10	Merck Patent Gmbh	Isoxazolderivate als Phosphodiesterase VII-Hemmer
DE19954707A1 (de)	1999-11-13	2001-05-17	Merck Patent Gmbh	Imidazolverbindungen als Phosphodiesterase VII-Hemmer
EP1329454A1 (de) *	2000-09-29	2003-07-23	Nippon Soda Co., Ltd.	Thienopyrimidinverbindungen und deren salze sowie verfahren zu deren herstellung
EP1193261A1 (de)	2000-10-02	2002-04-03	Warner-Lambert Company	Thiadiazole und ihre Verwendung als Phosphodiesterase-7 Inhibitoren
CN101100472A (zh) *	2001-04-30	2008-01-09	美国拜尔公司	4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物及其应用
EP1348701A1 (de)	2002-03-28	2003-10-01	Warner-Lambert Company LLC	2,4-disubstituierte Thiazol-5-yl-Amine als PDE7-Inhibitoren

2003
- 2003-01-23 ES ES200300172A patent/ES2217956B1/es not_active Expired - Fee Related
2004
- 2004-01-23 EP EP04704579A patent/EP1590352B1/de not_active Expired - Lifetime
- 2004-01-23 JP JP2006500010A patent/JP2006515604A/ja active Pending
- 2004-01-23 AT AT04704579T patent/ATE365742T1/de not_active IP Right Cessation
- 2004-01-23 CN CN200480007362A patent/CN100582112C/zh not_active Expired - Fee Related
- 2004-01-23 ES ES04704579T patent/ES2289475T3/es not_active Expired - Lifetime
- 2004-01-23 DE DE602004007239T patent/DE602004007239T2/de not_active Expired - Lifetime
- 2004-01-23 WO PCT/EP2004/000584 patent/WO2004065391A1/en not_active Ceased
- 2004-01-23 US US10/542,940 patent/US7662814B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2217956B1 (es)	2006-04-01
ES2217956A1 (es)	2004-11-01
EP1590352B1 (de)	2007-06-27
US7662814B2 (en)	2010-02-16
WO2004065391A1 (en)	2004-08-05
US20060229306A1 (en)	2006-10-12
JP2006515604A (ja)	2006-06-01
DE602004007239T2 (de)	2008-02-28
CN1761671A (zh)	2006-04-19
EP1590352A1 (de)	2005-11-02
ES2289475T3 (es)	2008-02-01
CN100582112C (zh)	2010-01-20
DE602004007239D1 (de)	2007-08-09

Legal Events

Date	Code	Title	Description
2007-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE602004007239D1 (de)	2007-08-09	4-AMINOTHIENOÄ2,3-dÜ PYRIMIDIN -6-CARBONITRIL-DERIVATIVE ZUR VERWENDUNG ALS PDE7 INHIBITOREN
ATE437872T1 (de)	2009-08-15	Proteinkinaseinhibitoren
MXPA05010958A (es)	2006-01-30	Derivados indazol como inhibidores jnk.
SG170101A1 (en)	2011-04-29	2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
GB0112348D0 (en)	2001-07-11	Compounds
MX2008013836A (es)	2008-11-10	Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
SG151260A1 (en)	2009-04-30	5-substituted-2-phenylamino-benzamides as mek inhibitors
WO2001064639A3 (en)	2002-02-28	Pde iv inhibiting amides, compositions and pharmaceutical use
ATE517882T1 (de)	2011-08-15	Chinolinderivate
NO20056030L (no)	2006-02-15	Nye pyridopyraziner og anvendelse derav som kinaseinhibitorer
NO20070837L (no)	2007-04-16	Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
MX2010006748A (es)	2010-08-18	Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
EA200600811A1 (ru)	2006-10-27	НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
NO20050851L (no)	2005-03-29	Kaspase-inhibitorer og anvendelser derav
WO2004108715A8 (en)	2005-12-01	3-aryloxy and 3-heteroaryloxy substituted benzo(b) thiophenes as therapeutic agents with pi3k activity
PT828728E (pt)	2003-06-30	Di-hidrobenzofuranos de fenilo
PL1682528T3 (pl)	2008-01-31	Pochodne benzo[b][1,4]dioksepiny
CY1109366T1 (el)	2014-07-02	Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
IL175875A0 (en)	2006-10-05	Substituted 1h-pyrrolo[3,2-b, 3,2-c and 2,3-c] pyridine-2-carboxamides and related analogs as inhibitors of casein kinase i epsilon
WO2006116733A3 (en)	2006-12-14	Protein kinase inhibitors
DE59610031D1 (de)	2003-02-06	Cyclohexyldihydrobenzofurane
TW200745136A (en)	2007-12-16	4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
NO20063768L (no)	2006-11-02	1H-tieno[2,3c] pyrazolderivater anvendelige som kinaseinhibitorer
ATE518858T1 (de)	2011-08-15	Pyrroloä3,2-cüpyridinderivate und herstellungsverfahren dafür
MX2007001267A (es)	2007-07-11	Derivados de naftiridinas 2,8-disustituidas.